This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrinology
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Musculoskeletal Conditions
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search
  • X (formerly Twitter) (opens in a new tab)
  • Bluesky (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:58827/feed
ISSN 2327-2236
Oncology
Vol. 2, Issue 2, 2015April 27, 2015 EDT

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia

Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe, Susan J. Blalock,
oncologyhematologytreatment interruptiontyrosine kinase inhibitorschronic myeloid leukemia
Copyright Logoccby-4.0 • https://doi.org/10.36469/9899

Articles in Vol. 2, Issue 2, 2015

Vol. 2, Issue 2, 2015
  • Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis
    William V. PadulaMiguel Cordero-ComaTaygan YilmazWilliam V. PadulaMichéal J. GallagherJonathan D. Campbell
  • Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
    Keith L. DavisBenjamin GutierrezTeresa ZyczynskiJames A. Kaye
  • Traumatic Brain Injury: Patient Characteristics, Hospital Costs and Trends Over Time
    Pankaj A. PatelPeter J. MallowMary VassarJohn A. RizzoBhavik J. PandyaDenise T. Kruzikas
  • A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival Data
    Gabriel TremblayPatrick HainesAndrew Briggs
  • Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients: Describing the Diagnostic Odyssey
    Renée JG ArnoldAndrew Layton
  • The Cost of an Operating Room Minute for Heart Valve Procedures
    Eugene A. GrossiMatthew MoorePeter J. MallowJohn A. Rizzo
  • Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
    Melea A. WardGang FangKristy L. RichardsChristine M. WalkoStephanie R. EarnshawLaura E. HappeSusan J. Blalock
  • Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
    Anke van EngenMontserrat CasamayorFidelma LoftusMartin CoenAndy GarnhamMaureen WattLarry Lacey
  • Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment
    Ken OkumuraHiroshi InoueMasahiro YasakaJuan Marcos GonzalezA. Brett HauberBennett LevitanZhong YuanJean Baptiste Briere
  • Comparison of Real-world Outcomes Between Patients Treated with Tapentadol ER or Oxycodone CR
    Mike DurkinJacqueline PesaJessica LopattoRachel HalpernDamon Van VoorhisStephanie Korrer
JHEOR
1.
Ward MA, Fang G, Richards KL, et al. Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia. JHEOR. 2015;2(2):181-191. doi:10.36469/9899
Save article as...▾

View more stats

Powered by Scholastica, the modern academic journal management system